Orthos Limited, a Cwmbran, UK-based spine and orthopaedic medical device company, has received a £835,000 equity and debt investment.
Orthos has secured a £500,000 equity investment from Finance Wales, a £60,000 angel follow-on investment and a £275,000 Welsh Assembly Government funding.
Orthos has a range of proprietary orthobiologic products focused on skeletal defect repair and spinal fusion on sale or in development. The capital infusion, in particular, will be used to bring its mouldable βGel synthetic bone substitute to market.
The bone substitute, which can be moulded by hand, has been specifically formulated for treating spinal bone defects and minimises the infection risks associated with bone implant surgery.
Founded by Alan Rorke in 1998, the company has recently relocated to Wales from Bristol and has also strengthened its management team with the appointment of industry experts, Robert Welsh as Chief Executive and Professor Christina Doyle as a Non-Executive Director.
In addition, Orthos also is planning to enter the vertebral compression fracture market.